Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer
NCT05399394Phase 2Unknown
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Jul 2016
- Primary completion
- Apr 2022
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, folinic acid and gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 4 months. Status: unknown.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracilfolinic acidgemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05399394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399394.